<DOC>
	<DOCNO>NCT02439541</DOCNO>
	<brief_summary>Phase I-II Clinical Trial-Safety efficacy umbilical cord derive mesenchymal stem cell ( UC-MSCs ) patient chronic heart ischemia cohort perspective study .</brief_summary>
	<brief_title>Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy Ischemic Cardiomyopathy</brief_title>
	<detailed_description>Phase I-II Clinical Trial-Safety efficacy umbilical-cord-derived mesenchymal stem cell ( UC-MSC ) patient chronic heart ischemia cohort prospective study . Forty patient select divide two group accord patient ' willingness stem cell treatment . The patient willing receive stem cell transplantation receive UC-MSCs coronary injection . The patient control group receive intervention . Every patient maintain standard treatment chronic heart ischemia , maximum tolerated dosage without side effect . The day infusion consider day zero . From moment , followup divide 0-1,1-3 , 3-6 , 6-12 month . Clinical result analyze completion 12 month followup .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Age 18 80 No option PCI CABG ( Angiographies evaluate independent interventional cardiologist ) . Maximal tolerable angina heart failure medication NYHA functional classification ( IIII ) Signed informed consent Severe liver renal dysfunction hemorrhagic diseases suitable PCI . Severe cerebral ischemic stroke cerebral hemorrhage within 6 month . History malignant disease within 5 inclusion suspect malignity Severe heart failure ( NYHA functional classification IV ) Diminished functional capacity reason COPD , alcoholic cardiomyopathy , viral myocarditis Clinical significant anemia , leukopenia , leukocytosis , thrombocythemia Clinical significant abnormal prothrombin partial thromboplastin time anticoagulation treatment pause treatment Patients reduce immune response treat immunosuppressive medication Combined severe infectious disease Pregnant fertile woman Socially mentally disability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cellular therapy</keyword>
	<keyword>Chronic ischemic heart disease</keyword>
	<keyword>phase 1/2 clinical study</keyword>
	<keyword>human umbilical cord mesenchymal stem cell</keyword>
	<keyword>ischemic heart disease</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>